HOME >> BIOLOGY >> NEWS
Results from open-label Raptiva study suggest continued benefit with long-term treatment

Genentech, Inc. and XOMA Ltd. today announced preliminary results from an open-label, multicenter trial evaluating the long-term safety and tolerability of continuous RaptivaTM (efalizumab) treatment in patients with moderate-to-severe psoriasis.

"The findings from this important open-label study on the long-term safety and efficacy of Raptiva are very encouraging and further support Raptiva's potential to address the unmet medical need of patients with moderate-to-severe psoriasis," said Hal Barron M.D., FACC, Genentech's vice president, Medical Affairs.

Alice Gottlieb, M.D., director of the Clinical Research Center at the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey presented data for patients receiving continuous Raptiva treatment for one year following an initial three months of treatment. The data were presented on Saturday, March 22 at the 61st annual American Academy of Dermatology meeting being held in San Francisco.

Response Rates with Continued Raptiva Treatment

A total of 339 patients were enrolled in this continuing open-label, multicenter study. 41 percent of patients (140/339) achieved 75 percent or greater improvement in Psoriasis Area and Severity Index (PASI) scores (PASI 75) and 82 percent (278/339) achieved PASI 50 or greater improvement after 12 weeks of 2 mg/kg/week Raptiva therapy. Patients who achieved a PASI 50 score or OLS (Overall Lesion Severity scale) of clear, minimal or mild at week 12 were eligible to enter the continuous treatment period. Of the original 339 patients, 290 patients who met the entry criteria for the maintenance period entered the continuous treatment phase of the study. For each successive three-month period of treatment, dropouts during that cohort period were counted as non-responders for that cohort, but were excluded from the subsequent cohorts.

Starting from week 13, the wee
'"/>

Contact: Emmy Tsui
emmy.tsui@ketchum.com
646-935-4019
Ketchum
24-Mar-2003


Page: 1 2 3 4 5

Related biology news :

1. Results of pivotal study for GlaxoSmithKlines Valtrex published in New England Journal of Medicine
2. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
3. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
4. Encouraging Results In Preclinical Studies Of Parkinsons Disease Gene Therapy
5. Quicker Implementation Of Research Results
6. Results Of Poisoning Visible In Urine
7. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
8. New Gene Therapy Technique Results In Efficient Gene Delivery
9. False Security: You Cant Always Believe The Results Of A Genetic Test
10. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
11. Results Of Hog-Stress Study May Lead To Better Management Methods

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/9/2018)... ... 09, 2018 , ... Controlled Contamination Services (CCS) is excited ... enable CCS to scale its business across the US and widen our reach ... and a need for a wide array of services to accommodate our current ...
(Date:11/7/2018)... ... November 07, 2018 , ... NDA Partners Chairman Carl ... with extensive experience in clinical trial management, including managing operations and trials focused ... Asia, has joined the firm as an Expert Consultant. , Prior to ...
(Date:11/6/2018)... (PRWEB) , ... November 06, 2018 , ... ... characteristics, that subsequently improve disease detection. Advanced systems can perform a complete blood ... subclasses of mature white blood cells. They also produce improved flagging of abnormal ...
Breaking Biology News(10 mins):
(Date:11/9/2018)... (PRWEB) , ... November 08, 2018 , ... ... integrator of custom industrial automation and IT solutions with 140 employees on both ... Automation Fair®, taking place at the Pennsylvania Convention Center on November 14 and ...
(Date:11/5/2018)... (PRWEB) , ... November 05, 2018 , ... ... and telemedicine company backed by Siemens Healthineers and several healthcare VC firms announces ... radiology solution and making a history by purchasing tokens and obtaining its first ...
(Date:10/31/2018)... ... 30, 2018 , ... Rooam , the premier payment platform for the ... After its acquisition of the Tally payment app, the leading payment platform in Chicago ... will grow its market share and increase the number of restaurant and bar locations ...
(Date:10/29/2018)... ... October 29, 2018 , ... PracticeMatch , a company that provides the ... physician career fairs planned for 2019. The company has expanded its offering of virtual ... the areas of the country which have the highest concentrations of resident and fellow ...
Breaking Biology Technology:
Cached News: